help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boulle, N.
Right arrow Articles by Le Bouc, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boulle, N.
Right arrow Articles by Le Bouc, Y.
Endocrinology Vol. 141, No. 9 3127-3136
Copyright © 2000 by The Endocrine Society

ARTICLES

Fibroblast Growth Factor-2 Inhibits the Maturation of Pro-Insulin-Like Growth Factor-II (Pro-IGF-II) and the Expression of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in the Human Adrenocortical Tumor Cell Line NCI-H295R1

Nathalie Boulle, Christine Gicquel, Armelle Logié, Rémi Christol, Jean-Jacques Feige and Yves Le Bouc

Laboratoire d’Explorations Fonctionnelles Endocriniennes (N.B., C.G., A.L., R.C., Y.L.), Hôpital Trousseau, 75012 Paris, France, and INSERM Unité U515, Hôpital Saint-Antoine, 75012 Paris, France; INSERM Unité 244 (J.-J.F.), DBMS/BRCE, CEA/Grenoble, 38054 Grenoble cedex 9, France

Address all correspondence and requests for reprints to: Nathalie Boulle, Laboratoire d’Explorations Fonctionnelles Endocriniennes, Hôpital Trousseau, 26 Avenue Arnold NETTER, 75012 Paris, France. E-mail: lab.endoc{at}trs.ap-hop-paris.fr

The IGF system is thought to play a major role in adrenocortical tumorigenesis. In this study, we used the NCI H295R cell line as a model to investigate the effects of fibroblast growth factor-2 (FGF-2), a potent mitogen for normal adrenal cells, on the proliferation and on the expression of the IGF system in cultured adrenocortical tumor cells. Three immunoreactive FGF-2 isoforms of molecular masses 18, 22, and 24 kDa were detected in H295R cell extracts. Recombinant human FGF-2 stimulated the proliferation of adrenocortical tumor cells in a dose- and time-dependent manner, with a maximal effect at a concentration of about 1 ng/ml. Treatment of H295R cells with 10 ng/ml FGF-2 for 7 days had no significant effect on IGF-II messenger RNA levels. However, a marked increase in levels of intracellular IGF-II protein was detected by immunoblotting. In contrast, FGF-2 induced a marked decrease in the amount of IGF-II protein secreted, with the disappearance of mature IGF-II and secretion of higher molecular forms of the growth factor, suggesting modifications of IGF-II processing. Cell cultures in the presence of brefeldin A (1 µg/ml), a specific inhibitor of protein secretion, suggested that FGF-2 did not increase IGF-II synthesis but instead inhibited the secretion of pro-IGF-II from H295R cells, thereby impairing the final steps of IGF-II processing to the mature 7.5-kDa peptide. At the same concentrations, FGF-2 also decreased both IGFBP-2 messenger RNA and secreted protein, which might increase IGF-II bioavailability. No proteolysis of IGFBP-2 was detected in FGF-2-conditioned medium. Altogether, these results indicate that FGF-2 is mitogenic for NCI H295R tumor cells and regulates the expression of both IGF-II and IGFBP-2 in this tumor model. Moreover, this study shows a novel effect of FGF-2, by which this growth factor modulates the processing of pro-IGF-II.




This article has been cited by other articles:


Home page
 J BiochemHome page
K. Yuasa, T. Masuda, C. Yoshikawa, M. Nagahama, Y. Matsuda, and A. Tsuji
Subtilisin-like Proprotein Convertase PACE4 is Required for Skeletal Muscle Differentiation
J. Biochem., September 1, 2009; 146(3): 407 - 415.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
M. Bielinska, H. Parviainen, S. Kiiveri, M. Heikinheimo, and D. B. Wilson
REVIEW PAPER: Origin and Molecular Pathology of Adrenocortical Neoplasms
Vet. Pathol., March 1, 2009; 46(2): 194 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R. Libe, A. Fratticci, and J. Bertherat
Adrenocortical cancer: pathophysiology and clinical management
Endocr. Relat. Cancer, March 1, 2007; 14(1): 13 - 28.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
M. Haase, M. Schott, S. R Bornstein, L. K Malendowicz, W. A Scherbaum, and H. S Willenberg
CITED2 is expressed in human adrenocortical cells and regulated by basic fibroblast growth factor
J. Endocrinol., February 1, 2007; 192(2): 459 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. N. West, G. A. Neale, S. Pounds, B. C. Figueredo, C. Rodriguez Galindo, M. A. D. Pianovski, A. G. Oliveira Filho, D. Malkin, E. Lalli, R. Ribeiro, et al.
Gene Expression Profiling of Childhood Adrenocortical Tumors
Cancer Res., January 15, 2007; 67(2): 600 - 608.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
R. Libe and J. Bertherat
Molecular genetics of adrenocortical tumours, from familial to sporadic diseases
Eur. J. Endocrinol., October 1, 2005; 153(4): 477 - 487.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Fassnacht, D. Weismann, S. Ebert, P. Adam, M. Zink, F. Beuschlein, S. Hahner, and B. Allolio
AKT Is Highly Phosphorylated in Pheochromocytomas But Not in Benign Adrenocortical Tumors
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4366 - 4370.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Miraki-Moud, A. B. Grossman, M. Besser, J. P. Monson, and C. Camacho-Hubner
A Rapid Method for Analyzing Serum Pro-Insulin-Like Growth Factor-II in Patients with Non-Islet Cell Tumor Hypoglycemia
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3819 - 3823.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. de Fraipont, M. El Atifi, N. Cherradi, G. Le Moigne, G. Defaye, R. Houlgatte, J. Bertherat, X. Bertagna, P.-F. Plouin, E. Baudin, et al.
Gene Expression Profiling of Human Adrenocortical Tumors Using Complementary Deoxyribonucleic Acid Microarrays Identifies Several Candidate Genes as Markers of Malignancy
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1819 - 1829.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Fassnacht, S. Hahner, I. A. Hansen, T. Kreutzberger, M. Zink, K. Adermann, F. Jakob, J. Troppmair, and B. Allolio
N-Terminal Proopiomelanocortin Acts as a Mitogen in Adrenocortical Tumor Cells and Decreases Adrenal Steroidogenesis
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2171 - 2179.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Lafont, M. Laurent, H. Thibout, F. Lallemand, Y. Le Bouc, A. Atfi, and C. Martinerie
The Expression of novH in Adrenocortical Cells Is Down-regulated by TGFbeta 1 through c-Jun in a Smad-independent Manner
J. Biol. Chem., October 18, 2002; 277(43): 41220 - 41229.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Hoeflich, R. Reisinger, H. Lahm, W. Kiess, W. F. Blum, H. J. Kolb, M. M. Weber, and E. Wolf
Insulin-like Growth Factor-binding Protein 2 in Tumorigenesis: Protector or Promoter?
Cancer Res., December 1, 2001; 61(24): 8601 - 8610.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society